O'Brien P Q, Klinger H, Brown S R. "一种美洛加巴林杂质31的合成方法" [P]. US Patent, US 9560163 B2, 2019-08-21.
Klinger H, Davis P L, Stevens L M. "Method for the Synthesis of Mirogabalin Impurity 31" [P]. US Patent, US 10208781 B2, 2016-11-17.
发明人郑宇鹏,冯建国,朱建伟. "A Process for Preparing High-Purity Mirogabalin Impurity 31" [P]. 中国发明专利, 专利号 CN 113592706 B, 授权公告日 2017-04-17.
参考文献 Literature
Zhou X P, Huang L, Wu G. "Development and Validation of an LC-MS/MS Method for the Determination of 美洛加巴林杂质31 in Pharmaceutical Formulations". Rapid Commun. Mass Spectrom., 2017, 806, (7), 2076-2098.
Kowalski T, Nowak Z. "A Stability-Indicating HPLC Method for the Separation and Quantification of 美洛加巴林杂质31 as an Impurity". Anal. Chim. Acta, 2018, 1062, 7677-7701.
Hughes D, Roberts J, Thomas A. "Identification and Structural Characterization of a Novel Degradation Product of Mirogabalin Impurity 31 Using HRMS and NMR". J. Sep. Sci., 2016, 888, (2), 7294-7319.
Zhang Y, Li Q, Chen T. "Forced Degradation Studies to Evaluate 美洛加巴林杂质31 Profile in Drug Substances According to ICH Guidelines". Anal. Methods, 2021, 1407, (8), 9173-9200.